Rare disease therapy developer, Immusoft, has signed a licensing agreement with Takeda Pharmaceutical with a total potential value of more than $900 million, to discover, develop and commercialize transformative cell therapies in rare inherited metabolic disorders with central nervous system manifestations and complications using Immusoft’s Immune System...